Emergency Use Authorization (EUA) for the Use of Monoclonal Antibody Therapies for Mild to Moderate COVID-19
From the Arkansas Department of Health on November 25:
On Nov 9, the U.S. Food and Drug Administration (FDA) issued an EUA to permit the emergency use of the unapproved product bamlanivimab (manufacturer Eli Lilly) for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
On Nov 21, FDA issued another EUA to permit the emergency use of the unapproved products casirivimab and imdevimab (manufacturer Regeneron) to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID19 and/or hospitalization.
The U.S. Department of Health and Human Services is allocating initial doses of these investigational monoclonal antibody to state health departments free of cost to be distributed within their territories.
Arkansas Department of Health, working in collaboration with the Arkansas Hospital Association has identified sites for administration of these monoclonal antibodies; and will be providing the medication to these locations.
